News
|
|
Undruggable? Not to Cloud Pharmaceuticals
Company meets challenge to design active molecules that inhibit "undruggable" targets linked with cancer recurrence and increased risk of mortality related to cardiovascular disease and sepsis
Research Triangle Park, NC (February 23, 2017) -- Cloud Pharmaceuticals, a cloud-based drug design and development company, was recently presented with a challenge by its research partners at the University of Florida - to design active molecules against a target considered to be "undruggable."
To succeed, the company needed to develop an inhibitor of the beta common receptor (bCR) to block erythropoietin (EPO) side effects. Patients receiving elevated levels of EPO have increased risk of mortality due to excessive cardiovascular disease, higher mortality in sepsis patients, increased probability of cancer recurrence in breast cancer patients.
By applying its Quantum Molecular Design process, Cloud Pharmaceuticals was able to design several peptides to inhibit this previously un-druggable protein-protein interaction target. Successful activity was measured in cell and animal models.
"We are proud of this demonstration of the power and versatility of our technology and process," says Don Van Dyke, Chief Operating Officer at Cloud Pharmaceuticals. "We look forward to more challenges like this to help bring medicines to market faster that improve health and well-being."
Company meets challenge to design active molecules that inhibit "undruggable" targets linked with cancer recurrence and increased risk of mortality related to cardiovascular disease and sepsis
Research Triangle Park, NC (February 23, 2017) -- Cloud Pharmaceuticals, a cloud-based drug design and development company, was recently presented with a challenge by its research partners at the University of Florida - to design active molecules against a target considered to be "undruggable."
To succeed, the company needed to develop an inhibitor of the beta common receptor (bCR) to block erythropoietin (EPO) side effects. Patients receiving elevated levels of EPO have increased risk of mortality due to excessive cardiovascular disease, higher mortality in sepsis patients, increased probability of cancer recurrence in breast cancer patients.
By applying its Quantum Molecular Design process, Cloud Pharmaceuticals was able to design several peptides to inhibit this previously un-druggable protein-protein interaction target. Successful activity was measured in cell and animal models.
"We are proud of this demonstration of the power and versatility of our technology and process," says Don Van Dyke, Chief Operating Officer at Cloud Pharmaceuticals. "We look forward to more challenges like this to help bring medicines to market faster that improve health and well-being."
About Cloud Pharmaceuticals, Inc.
Cloud Pharmaceuticals is committed to improving health and well-being through the computational design and rapid development of new therapies. Its proprietary Quantum Molecular Design process combines artificial intelligence (AI) and cloud computing to search virtual molecular space and applies along sophisticated molecular modeling to design novel drugs. The process enables faster drug development progress at lower cost and a higher success rate and better targeting of hard-to-drug indications. The company partners at all stages of drug development – from discovery through the clinic – and is building an extensive product pipeline that spans a wide range of indications.
Cloud Pharmaceuticals is committed to improving health and well-being through the computational design and rapid development of new therapies. Its proprietary Quantum Molecular Design process combines artificial intelligence (AI) and cloud computing to search virtual molecular space and applies along sophisticated molecular modeling to design novel drugs. The process enables faster drug development progress at lower cost and a higher success rate and better targeting of hard-to-drug indications. The company partners at all stages of drug development – from discovery through the clinic – and is building an extensive product pipeline that spans a wide range of indications.
###
